SAN
DIEGO, Nov. 27, 2023 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
members of the senior leadership team are scheduled to present and
host investor meetings at the following investor
conferences.
Details on the presentations are as follow:
Event:
|
|
|
|
Piper Sandler
35th Annual Healthcare Conference
|
Presenter:
|
|
|
|
Nicole LaBrosse, Chief
Financial Officer
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Wednesday, November
29th, 2023
|
Presentation
Time:
|
|
|
|
5:00 a.m. PT / 8:00
a.m. ET
|
Location:
|
|
|
|
New York, NY
|
|
|
|
|
|
Event:
|
|
|
|
6th Annual
Evercore ISI HealthCONx Conference
|
Presenter:
|
|
|
|
Helen Torley, President
and Chief Executive Office
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Wednesday, November
29th, 2023
|
Presentation
Time:
|
|
|
|
9:30 a.m. PT / 12:30
p.m. ET
|
Location:
|
|
|
|
Miami, FL
|
|
|
|
|
|
A live audio webcast of the presentations will be available in
the Investor Relations section of the Company's website.
Replays of the audio webcasts will be available for 90 days
following the conference.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's
commercially-validated solution is used to facilitate the delivery
of injected drugs and fluids in order to reduce the treatment
burden to patients. Having touched more than 700,000 patient lives
in post-marketing use in seven commercialized products across more
than 100 global markets, Halozyme has licensed its ENHANZE®
technology to leading pharmaceutical and biotechnology companies
including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers
Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare,
Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED® and TLANDO® and partnered commercial products
and ongoing product development programs with several
pharmaceutical companies including Teva Pharmaceuticals and Idorsia
Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Dawn Schottlandt
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-301997522.html
SOURCE Halozyme Therapeutics, Inc.